SG10201801524PA - A therapeutic agent for use in the treatment of infections - Google Patents

A therapeutic agent for use in the treatment of infections

Info

Publication number
SG10201801524PA
SG10201801524PA SG10201801524PA SG10201801524PA SG10201801524PA SG 10201801524P A SG10201801524P A SG 10201801524PA SG 10201801524P A SG10201801524P A SG 10201801524PA SG 10201801524P A SG10201801524P A SG 10201801524PA SG 10201801524P A SG10201801524P A SG 10201801524PA
Authority
SG
Singapore
Prior art keywords
infections
treatment
therapeutic agent
therapeutic
agent
Prior art date
Application number
SG10201801524PA
Inventor
Adrian Fellows
Original Assignee
Aga Nanotech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aga Nanotech Ltd filed Critical Aga Nanotech Ltd
Publication of SG10201801524PA publication Critical patent/SG10201801524PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/132Amines having two or more amino groups, e.g. spermidine, putrescine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/327Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/40Peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201801524PA 2014-04-01 2015-03-24 A therapeutic agent for use in the treatment of infections SG10201801524PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1405874.7A GB201405874D0 (en) 2014-04-01 2014-04-01 A therapeutic agent for use in the treatment of infections
GBGB1415063.5A GB201415063D0 (en) 2014-04-01 2014-08-26 A therapeutic agent for use in the treatment of infections

Publications (1)

Publication Number Publication Date
SG10201801524PA true SG10201801524PA (en) 2018-04-27

Family

ID=50737835

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201608093WA SG11201608093WA (en) 2014-04-01 2015-03-24 A therapeutic agent for use in the treatment of infections
SG10201801524PA SG10201801524PA (en) 2014-04-01 2015-03-24 A therapeutic agent for use in the treatment of infections

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201608093WA SG11201608093WA (en) 2014-04-01 2015-03-24 A therapeutic agent for use in the treatment of infections

Country Status (16)

Country Link
US (2) US9913805B2 (en)
EP (2) EP3125874B1 (en)
JP (1) JP6573286B2 (en)
KR (2) KR102359855B1 (en)
CN (1) CN106456557B (en)
AU (1) AU2015242495B2 (en)
CA (1) CA2943431C (en)
DK (1) DK3125874T3 (en)
ES (2) ES2953755T3 (en)
GB (3) GB201405874D0 (en)
IL (1) IL247969B (en)
MX (1) MX2016012757A (en)
NZ (1) NZ724298A (en)
SG (2) SG11201608093WA (en)
WO (1) WO2015150722A1 (en)
ZA (1) ZA201606387B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405874D0 (en) * 2014-04-01 2014-05-14 Aga Nanotech Ltd A therapeutic agent for use in the treatment of infections
CN107281220B (en) * 2016-03-31 2020-02-14 中国科学院上海硅酸盐研究所 Mesoporous silica-based active oxygen (ROS) radiotherapy sensitizer and preparation method thereof
CN106860032B (en) * 2016-10-25 2021-04-09 咏达生医材料股份有限公司 Gaseous skin oxygen supply whitening product and application thereof
JP2019194162A (en) * 2018-05-01 2019-11-07 ツァ ギャリー Ventilation material comprising whitening and heating function by oxygen supply to skin
GB2592911B (en) * 2020-02-28 2023-06-28 Aga Nanotech Ltd A plasma-activatable wound dressing for treatment of infections
GB202005556D0 (en) 2020-04-16 2020-06-03 Aga Nanotech Ltd Covid face mask

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908614A (en) * 1995-08-15 1999-06-01 Montgomery; Robert Eric Peroxidase-activating oral compositions
ES2249856T3 (en) * 1999-07-02 2006-04-01 Cognis Ip Management Gmbh MICROCAPSULES - IV.
AU4477001A (en) * 2000-04-18 2001-10-30 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
KR100342746B1 (en) * 2000-06-27 2002-07-03 김찬화 Controlled release preparation of insulin and its method
GB0411304D0 (en) * 2004-05-21 2004-06-23 Fellows Adrian N An antimicrobial composition
US20060088498A1 (en) * 2004-10-27 2006-04-27 Truox, Inc. Anti-microbial composition using in-situ generation of an oxidizing agent
EP1919507A2 (en) * 2005-08-04 2008-05-14 Thomas William Rademacher Nanoparticles comprising antibacterial ligands
KR20070071225A (en) * 2005-12-29 2007-07-04 애경산업(주) Tooth whitening composition
GB0711952D0 (en) * 2007-06-20 2007-08-01 King S College London Microspheres
US20110218140A1 (en) * 2008-02-25 2011-09-08 Gonsalves Kenneth E Biodegradable therapeutic nanoparticles containing an antimicrobial agent
CA2946195A1 (en) * 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
US8969282B2 (en) * 2009-02-05 2015-03-03 American Sterilizer Company Low odor, hard surface sporicide
WO2010129309A2 (en) * 2009-04-27 2010-11-11 Premier Dental Products Compnay Microencapsulated compositions and methods for tissue mineralization
KR101136028B1 (en) * 2009-04-27 2012-04-18 한양대학교 산학협력단 Manufacturing method of porous microsphere
NZ600269A (en) * 2009-05-20 2014-02-28 Dec Int Nz Ltd Delivery device for treatment of mastitis
US9187594B2 (en) * 2010-02-09 2015-11-17 The Regents Of The University Of Michigan Nano-fibrous microspheres and methods for making the same
ES2527193T3 (en) * 2010-07-09 2015-01-21 Innocore Technologies B.V. Multi-block segmented copolymers of separate biodegradable phases and release of biologically active polypeptides
WO2012074588A2 (en) * 2010-08-30 2012-06-07 President And Fellows Of Harvard College Shear controlled release for stenotic lesions and thrombolytic therapies
GB201405874D0 (en) * 2014-04-01 2014-05-14 Aga Nanotech Ltd A therapeutic agent for use in the treatment of infections

Also Published As

Publication number Publication date
EP3848022A1 (en) 2021-07-14
CN106456557B (en) 2021-02-05
US20170079930A1 (en) 2017-03-23
SG11201608093WA (en) 2016-10-28
US9913805B2 (en) 2018-03-13
KR20220021029A (en) 2022-02-21
ES2855985T3 (en) 2021-09-27
EP3848022B1 (en) 2023-06-07
EP3125874B1 (en) 2020-12-30
GB201405874D0 (en) 2014-05-14
GB201617053D0 (en) 2016-11-23
KR102482597B1 (en) 2022-12-29
JP2017510648A (en) 2017-04-13
MX2016012757A (en) 2017-04-27
ES2953755T3 (en) 2023-11-15
IL247969B (en) 2018-12-31
ZA201606387B (en) 2017-11-29
EP3125874A1 (en) 2017-02-08
US10933026B2 (en) 2021-03-02
GB2538923B (en) 2020-03-25
AU2015242495A1 (en) 2016-10-06
CA2943431C (en) 2022-08-23
DK3125874T3 (en) 2021-03-22
KR102359855B1 (en) 2022-02-08
JP6573286B2 (en) 2019-09-11
US20180207105A1 (en) 2018-07-26
WO2015150722A1 (en) 2015-10-08
AU2015242495B2 (en) 2020-04-30
GB201415063D0 (en) 2014-10-08
EP3848022C0 (en) 2023-06-07
CA2943431A1 (en) 2015-10-08
CN106456557A (en) 2017-02-22
NZ724298A (en) 2022-07-01
GB2538923A (en) 2016-11-30
KR20160144408A (en) 2016-12-16

Similar Documents

Publication Publication Date Title
IL250685A0 (en) Cytotoxicity-inducing therapeutic agent
GB201403093D0 (en) Therapeutic compounds and their use
IL254142B (en) Tradipitant for use in the treatment of a tradipitant-responsive disease or condition
GB201410816D0 (en) Therapeutic agents
IL250990A0 (en) Human therapeutic agents
IL247969B (en) A therapeutic agent for use in the treatment of infections
GB201502412D0 (en) Therapeutic use
GB201617064D0 (en) Compounds and their therapeutic use
GB201608797D0 (en) Therapeutic use
GB201410815D0 (en) Therapeutic agents
GB201410817D0 (en) Therapeutic agents
PL3160464T3 (en) 6-hydroxybuspirone for use in the treatment of movement disorders
HK1256164A1 (en) Agents for use in the treatment of glioma
IL246855A0 (en) Agents for use in the treatment of retinal inflammation
HUE058645T2 (en) Medicament for use in treating gout
GB201418809D0 (en) Therapeutic agents and uses thereof
GB201615844D0 (en) Agents for use in therapy
GB201409653D0 (en) Pyrrolobenzodiazepine therapeutic agents
HK1217430A1 (en) Surface treatment agent
GB201506786D0 (en) Therapeutic use
GB201911521D0 (en) Therapeutic agent
GB201516109D0 (en) Therapeutic agent
GB201506944D0 (en) Therapeutic treatment
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use